Pharvaris N.V. (NASDAQ:PHVS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Pharvaris N.V. (NASDAQ:PHVS) have earned a consensus rating of “Moderate Buy” from the twelve ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $40.5556.

PHVS has been the topic of several recent analyst reports. Oppenheimer lifted their price target on shares of Pharvaris from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Morgan Stanley raised their target price on shares of Pharvaris from $37.00 to $41.00 and gave the stock an “overweight” rating in a research report on Thursday, December 4th. Wedbush boosted their price target on shares of Pharvaris from $27.00 to $30.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Leerink Partners set a $38.00 price target on shares of Pharvaris in a research note on Wednesday, December 3rd. Finally, HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Pharvaris in a report on Wednesday, December 3rd.

Hedge Funds Weigh In On Pharvaris

A number of hedge funds have recently bought and sold shares of PHVS. TFG Asset Management GP Ltd increased its position in shares of Pharvaris by 48.1% during the 2nd quarter. TFG Asset Management GP Ltd now owns 188,100 shares of the company’s stock valued at $3,311,000 after purchasing an additional 61,105 shares during the last quarter. TD Asset Management Inc grew its position in Pharvaris by 27.4% during the second quarter. TD Asset Management Inc now owns 99,510 shares of the company’s stock valued at $1,751,000 after buying an additional 21,388 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in Pharvaris during the second quarter valued at approximately $57,000. HighVista Strategies LLC increased its holdings in Pharvaris by 4.3% during the second quarter. HighVista Strategies LLC now owns 23,739 shares of the company’s stock valued at $418,000 after buying an additional 971 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the period.

Pharvaris Stock Performance

NASDAQ PHVS opened at $26.45 on Monday. The company has a 50-day simple moving average of $26.04 and a two-hundred day simple moving average of $24.27. Pharvaris has a 12-month low of $11.51 and a 12-month high of $29.80.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.